Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company dedicated to overcoming cancer drug resistance and immune suppression, announced that its CEO and Chairman, John Yu, MD, will deliver a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference. The event is scheduled to take place in person from Sept. 14-16, 2026, at the Lotte New York Palace Hotel. This presentation is expected to provide investors with insights into the company's strategic direction and the progress of its lead candidate, ENV-105.
The significance of this presentation lies in Kairos Pharma's innovative approach to oncology. The company utilizes structural biology to design therapeutics that address two fundamental challenges in cancer treatment: drug resistance and immune suppression. ENV-105, its lead antibody, targets CD105, a protein that has been identified as a key driver of resistance and disease relapse following standard therapy. By targeting CD105, ENV-105 aims to reverse this resistance and restore the effectiveness of conventional treatments across multiple cancer types. This could potentially improve outcomes for patients who have limited options due to resistance.
The announcement comes at a time when the oncology field is increasingly focused on combination therapies and mechanisms to overcome resistance. Kairos Pharma's approach is particularly noteworthy because it targets a specific molecular pathway that is implicated in resistance across various cancers, rather than a single tumor type. If successful, ENV-105 could become a cornerstone of combination regimens, enhancing the efficacy of existing drugs.
Investors and industry observers will be keen to hear Dr. Yu's presentation for updates on clinical development timelines and any data that may support the therapeutic potential of ENV-105. The conference provides a platform for the company to articulate its value proposition to a broader investment audience.
Kairos Pharma is based in Los Angeles, California, and is listed on the NYSE American under the ticker symbol KAPA. The company's focus on structural biology sets it apart in the competitive oncology landscape, as it seeks to understand the molecular underpinnings of resistance at a detailed level.
For more information about Kairos Pharma and its latest updates, interested parties are encouraged to visit the company's newsroom at https://ibn.fm/KAPA.
